Shots: The filling is based on the results of P-III IMpassion130 study, assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with 1L unresectable LA/M TNBC in ratio (1:1) P-III IMpassion130 study results: mPFS (7.2 vs 5.5mos.); OS (25.0 vs 15.5mos.); no new safety signals, Presented at ESMO 2018. The expected FDA approval […]Read More
Shots: The P-III IMpower130 study involves assessing of Tecentriq (atezolizumab) + CT (carboplatin and nab-paclitaxel) vs CT (carboplatin and nab-paclitaxel) in ratio (2:1) in 723 patients with stage IV non-sq NSCLC in ITT-WT population P-III IMpower130 study results: mOS (18.6 vs 13.9); ORR (49.2% vs 31.9%); mDOR (8.4 vs 6.1 mos.); mPFS (7.0 vs 5.5 […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
